OpenNashEarnings

Zoetis (ZTS) · Pharmaceuticals

Zoetis Q2 2026 earnings: summary, key numbers & outlook

Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026

Slides (24 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Zoetis is adapting to a pressured U.S. Companion Animal market with targeted promotions, the VitalRADS diagnostics acquisition and the Lenivia and Portela launches, while Livestock and International carry growth.

U.S. Companion Animal sales fell 11% as lower clinic visits, pet owner price sensitivity and promotion-led competition hit the dermatology and Simparica Trio franchises. Generic competition on Cerenia and Convenia and lower Librela sales added to the decline. Livestock grew 23% in the U.S. on cattle and poultry, and International Companion Animal grew 5% led by parasiticides. Lenivia and Portela launched in Canada and the EU.

Management is defending share through targeted sales, marketing and gross-to-net investment, a new U.S. commercial leader and further acquisitions, while pointing to a pipeline of more than 12 potential blockbusters. The main tension is that promotions and rebates may protect volume while dermatology in-clinic share fell 10pp year over year, and some of the Livestock lift from screwworm demand is expected to normalize in the second half.

No call transcript for this quarter, so this summary also draws on: Webull (Benzinga transcript) ↗.

Slides & documents

Open the slide deck (PDF, 24 pages) ↗

Zoetis Q2 2026 slide deck, page 1Zoetis Q2 2026 slide deck, page 2Zoetis Q2 2026 slide deck, page 3Zoetis Q2 2026 slide deck, page 4Zoetis Q2 2026 slide deck, page 5Zoetis Q2 2026 slide deck, page 6

Showing the first 6 of 24 pages.

From Zoetis investor relations

SEC filing

Key numbers

Revenue · GAAP
$2.5B

flat versus the second quarter of 2025

Net income · GAAP
$691 million

decreasing 5% on a reported basis

Diluted EPS · GAAP
$1.65

up 1% on a reported basis

Segment or metricValueChange
U.S. Companion Animal$1.0B(11)% reported and organic operational
U.S. Livestock$222.0M23% reported and organic operational
International Companion Animal$664.0M8% reported, 5% organic operational
International Livestock$509.0M8% reported, 6% organic operational
Key Dermatology395.0M(16)% organic operational
Simparica franchise442.0M0% organic operational
OA Pain mAbs147.0M(3)% organic operational
Companion animal diagnostics118.0M12% organic operational
Where each number comes from
  • Revenue: “Revenue | $2,468 | $2,474 | — | $4,730 | $4,672 | 1 Costs and expenses: Cost of sales | 673 | 664 | 1”
  • Net income: “Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis.”
  • Diluted EPS: “Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis.”
  • U.S. Companion Animal: “U.S.: Companion Animal | $1,044 | $1,176 | (11)% | —% | (11)% | —% | (11)%”
  • U.S. Livestock: “Livestock | 222 | 180 | 23% | —% | 23% | —% | 23% Total U.S. Revenue | $1,266 | $1,356 | (7)%”
  • International Companion Animal: “International: Companion Animal | $664 | $614 | 8% | 3% | 5% | —% | 5%”
  • International Livestock: “Livestock | 509 | 471 | 8% | 4% | 4% | (2)% | 6% Total International Revenue | $1,173”
  • Key Dermatology: “Key Dermatology 395 469 (16)% —% —% (16)%”
  • Simparica franchise: “Simparica franchise 442 437 1% 1% —% —%”
  • OA Pain mAbs: “OA Pain mAbs 147 150 (2)% 1% —% (3)%”
  • Companion animal diagnostics: “Companion animal diagnostics 118 104 13% 1% —% 12%”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$2.5B−0.2%+9.1%
Net income$691.0M−4.8%+15.0%
Diluted EPS$1.65+1.2%+16.2%
Free cash flow$538.0M+17.2%+84.9%

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Revenuefull year 2026$9.120 billion to $9.320 billion
Adjusted diluted EPSfull year 2026$6.15 to $6.25
Reported diluted EPSfull year 2026$5.55 to $5.65
Adjusted net incomefull year 2026$2.570 billion to $2.620 billion
Adjusted cost of sales as a percentage of revenuefull year 2026Approximately 29.0%
Adjusted SG&A expensesfull year 2026$2,330 to $2,380
Adjusted R&D expensesfull year 2026$720 to $730

Key takeaways

  1. U.S. dermatology share fell sharply under competition

    Zoetis's U.S. dermatology in-clinic share was ~86% in Q2, down 5pp from the prior quarter and 10pp from a year earlier. Management is raising targeted sales, marketing and gross-to-net investment rather than cutting list prices.

  2. Simparica Trio is gaining abroad but slipping in the U.S.

    International Simparica Trio revenue rose 34% organically on market share gains, while its U.S. in-clinic share slipped to ~21%. Zoetis is responding with competitive pricing, pet owner promotions and competitive capture programs.

  3. Lenivia and Portela launch in Canada and Europe

    The long-acting monoclonal antibody pain therapies for dogs and cats, which give up to three months of relief per injection, launched in Canada and the EU and were approved in Great Britain. Management cites encouraging early experience and accelerated the launches.

  4. Livestock and Diagnostics offset Companion Animal weakness

    U.S. Livestock grew 23% on beef producer economics, poultry vaccines and Dectomax demand tied to New World screwworm, with normalization expected in the second half. Companion animal diagnostics grew 12%, and VitalRADS adds teleradiology.

  5. Guidance cut assumes persistent market softness

    Full-year organic operational revenue guidance moved from growth of 2% to 5% to a decline of (3)% to (1)%. The assumptions cite softer demand, price sensitivity, promotion-led competition and Derm/Paras share losses.

Charts

Revenue$2.5B−0.2% y/yQ2 2026
Q4 2024: $2.3B (worked out from the annual figure)Q4 ’24$2.3BQ1 2025: $2.2BQ1 ’25$2.2BQ2 2025: $2.5BQ2 ’25$2.5BQ3 2025: $2.4BQ3 ’25$2.4BQ4 2025: $2.4B (worked out from the annual figure)Q4 ’25$2.4BQ1 2026: $2.3BQ1 ’26$2.3BQ2 2026: $2.5BQ2 ’26$2.5BQ3 2026: $2.4BQ3 ’26$2.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$2.3B *
Q1 2025$2.2B
Q2 2025$2.5B
Q3 2025$2.4B
Q4 2025$2.4B *
Q1 2026$2.3B
Q2 2026$2.5B
Q3 2026$2.4B
Diluted EPS (GAAP)$1.65+1.2% y/yQ2 2026
Q1 2025: $1.34Q1 ’25$1.34Q2 2025: $1.63Q2 ’25$1.63Q3 2025: $1.63Q3 ’25$1.63Q1 2026: $1.42Q1 ’26$1.42Q2 2026: $1.65Q2 ’26$1.65Q3 2026: $1.44Q3 ’26$1.44
Data
Q1 2025$1.34
Q2 2025$1.63
Q3 2025$1.63
Q1 2026$1.42
Q2 2026$1.65
Q3 2026$1.44

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Free cash flow$538.0M+17.2% y/yQ2 2026
Q4 2024: $689.0MQ4 ’24$689.0MQ1 2025: $337.0MQ1 ’25$337.0MQ2 2025: $459.0MQ2 ’25$459.0MQ3 2025: $798.0MQ3 ’25$798.0MQ4 2025: $689.0MQ4 ’25$689.0MQ1 2026: $291.0MQ1 ’26$291.0MQ2 2026: $538.0MQ2 ’26$538.0MQ3 2026: $717.0MQ3 ’26$717.0M
Data
Q4 2024$689.0M
Q1 2025$337.0M
Q2 2025$459.0M
Q3 2025$798.0M
Q4 2025$689.0M
Q1 2026$291.0M
Q2 2026$538.0M
Q3 2026$717.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is pressuring Zoetis's U.S. Companion Animal business?

Lower clinic visits, pet owner price sensitivity and promotion-led competition reduced demand, especially for dermatology and Simparica Trio. Generic competition on Cerenia and Convenia and lower Librela sales also contributed to the 11% decline.

How is Zoetis responding to competition?

It is appointing new U.S. commercial leadership, expanding targeted promotion and rebate levers, and shifting advertising and promotion spending to its highest-return programs. It is also using competitive pricing and pet owner promotions on Simparica Trio.

What are Lenivia and Portela and where have they launched?

They are long-acting monoclonal antibody therapies that give dogs and cats up to three months of osteoarthritis pain relief from a single injection. They launched in Canada and the EU, were approved in Great Britain, and Lenivia was also approved in Switzerland.

What is Zoetis doing in diagnostics?

It completed the acquisition of VitalRADS, a veterinary teleradiology platform, and plans to acquire Neogen's animal genomics business. It also expanded Vetscan Opticell, and companion animal diagnostics grew 12% organically.

Where is Zoetis seeing growth despite the weak U.S. Companion Animal market?

Livestock grew 11% organically, with cattle and poultry strong, and International revenue grew 6%. Emerging markets other than those listed grew 21% organically.